/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/hem---leukemia/,

/clinical/cckm-tools/content/beacon-protocols/hem---leukemia/name-96803-en.cckm

201611326

page

100

UWHC,UWMF,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Hem - Leukemia

CSC HEM Dasatinib(28D:1-28) VER 10-3-16 (HL 1888)

CSC HEM Dasatinib(28D:1-28) VER 10-3-16 (HL 1888) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Hem - Leukemia


CSC HEM DASATINIB(28D:1-28) VER: 10-3-16 – Properties
Pre-Cycle – 11/14/2016 through 11/20/2016 (7 days), Planned
Day 1, Pre-Cycle – Planned for 11/14/2016
Treatment Plan Information
Treatment Plan Summary
DISEASE: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); THERAPY: dasatinib 140 mg by mouth daily;
CYCLE LENGTH: 28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days;
COURSE: until disease progression.
Treatment Plan Summary (2)
DISEASE: Chronic Myeloid Leukemia (Chronic Phase); THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 28 days;
COURSE: 3 cycles followed by THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until disease
progression.
Treatment Plan Summary (3)
DISEASE: Chronic Myeloid Leukemia (Accelerated/Blast Phase); THERAPY: dasatinib 140 mg by mouth daily ; CYCLE LENGTH:
28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until
disease progression.
Consent
Verify Consent
Verify informed consent has been obtained.
Pre-Labs
CBC WITH DIFFERENTIAL
Expected-S Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S Approximate, Expires-S+365, Routine
AST/SGOT
Expected-S Approximate, Expires-S+365, Routine
ALT/SGPT
Expected-S Approximate, Expires-S+365, Routine
Cycle 1 – 11/21/2016 through 12/18/2016 (28 days), Planned
Day 1, Cycle 1 – Planned for 11/21/2016
Treatment Plan Information
Reference Information (1)
ACUTE LYMPHOBLASTIC LEUKEMIA: Ottmann O, et al. Blood. 2007; 110(7):2309-15
Reference Information (2)
CHRONIC MYELOGENOUS LEUKEMIA: Kantarjian H, et al. N Engl J Med. 2010; 362(24):2260-70.
Treatment Plan Summary
DISEASE: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); THERAPY: dasatinib 140 mg by mouth daily;
CYCLE LENGTH: 28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days;
COURSE: until disease progression.
Treatment Plan Summary (2)
DISEASE: Chronic Myeloid Leukemia (Chronic Phase); THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 28 days;
COURSE: 3 cycles followed by THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until disease
progression.
Treatment Plan Summary (3)
DISEASE: Chronic Myeloid Leukemia (Accelerated/Blast Phase); THERAPY: dasatinib 140 mg by mouth daily ; CYCLE LENGTH:
28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until
disease progression.
Consent
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/21/2016 2:09:48 PM Page 1 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC with DIFF, Total Bilirubin, AST, ALT
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Total Bilirubin greater
than 2.8 mg/dL or AST or ALT greater than 2.5 X ULN.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Treatment Medications
See Take Home Medication(s)
Refer to the take home medications section for the following treatment medication(s): dasatinib (dispensed Day 1 of Cycle 1 only -
subsequent refills will be ordered through the medication activity).
Take Home Medications (delete all that do not apply)
dasatinib (SPRYCEL) 20 MG tab
Take by mouth. No grapefruit products., R-0, starting S, Local Printer
dasatinib (SPRYCEL) 50 MG tab
Take by mouth. No grapefruit products., R-0, starting S, Local Printer
dasatinib (SPRYCEL) 70 MG tab
Take by mouth. No grapefruit products., R-0, starting S, Local Printer
dasatinib (SPRYCEL) 100 MG tab
Take by mouth. No grapefruit products., R-0, starting S, Local Printer
Follow-Up
DAY 29 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC with DIFF, Total Bilirubin, AST, ALT
Cycle 2 – 12/19/2016 through 1/15/2017 (28 days), Planned
Day 1, Cycle 2 – Planned for 12/19/2016
Treatment Plan Information
Treatment Plan Summary
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/21/2016 2:09:48 PM Page 2 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

DISEASE: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); THERAPY: dasatinib 140 mg by mouth daily;
CYCLE LENGTH: 28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days;
COURSE: until disease progression.
Treatment Plan Summary (2)
DISEASE: Chronic Myeloid Leukemia (Chronic Phase); THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 28 days;
COURSE: 3 cycles followed by THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until disease
progression.
Treatment Plan Summary (3)
DISEASE: Chronic Myeloid Leukemia (Accelerated/Blast Phase); THERAPY: dasatinib 140 mg by mouth daily ; CYCLE LENGTH:
28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until
disease progression.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITH DIFFERENTIAL
Expected-S+28 Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S+28 Approximate, Expires-S+365, Routine
AST/SGOT
Expected-S+28 Approximate, Expires-S+365, Routine
ALT/SGPT
Expected-S+28 Approximate, Expires-S+365, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC with DIFF, Total Bilirubin, AST, ALT
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Total Bilirubin greater
than 2.8 mg/dL or AST or ALT greater than 2.5 X ULN.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, dasatinib will be ordered through the medication activity after the initial order.
Follow-Up
DAY 29 FOLLOW-UP
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/21/2016 2:09:48 PM Page 3 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC with DIFF, Total Bilirubin,
AST, ALT
Cycle 3 – 1/16/2017 through 2/12/2017 (28 days), Planned
Day 1, Cycle 3 – Planned for 1/16/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); THERAPY: dasatinib 140 mg by mouth daily;
CYCLE LENGTH: 28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days;
COURSE: until disease progression.
Treatment Plan Summary (2)
DISEASE: Chronic Myeloid Leukemia (Chronic Phase); THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 28 days;
COURSE: 3 cycles followed by THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until disease
progression.
Treatment Plan Summary (3)
DISEASE: Chronic Myeloid Leukemia (Accelerated/Blast Phase); THERAPY: dasatinib 140 mg by mouth daily ; CYCLE LENGTH:
28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until
disease progression.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITH DIFFERENTIAL
Expected-S+28 Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S+28 Approximate, Expires-S+365, Routine
AST/SGOT
Expected-S+28 Approximate, Expires-S+365, Routine
ALT/SGPT
Expected-S+28 Approximate, Expires-S+365, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC with DIFF, Total Bilirubin, AST, ALT
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Total Bilirubin greater
than 2.8 mg/dL or AST or ALT greater than 2.5 X ULN.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/21/2016 2:09:48 PM Page 4 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, dasatinib will be ordered through the medication activity after the initial order.
Follow-Up
DAY 29 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC with DIFF, Total Bilirubin, AST, ALT
Cycle 4 – 2/13/2017 through 5/7/2017 (84 days), Planned
Day 1, Cycle 4 – Planned for 2/13/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); THERAPY: dasatinib 140 mg by mouth daily;
CYCLE LENGTH: 28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days;
COURSE: until disease progression.
Treatment Plan Summary (2)
DISEASE: Chronic Myeloid Leukemia (Chronic Phase); THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 28 days;
COURSE: 3 cycles followed by THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until disease
progression.
Treatment Plan Summary (3)
DISEASE: Chronic Myeloid Leukemia (Accelerated/Blast Phase); THERAPY: dasatinib 140 mg by mouth daily ; CYCLE LENGTH:
28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until
disease progression.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITH DIFFERENTIAL
Expected-S+28 Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S+28 Approximate, Expires-S+365, Routine
AST/SGOT
Expected-S+28 Approximate, Expires-S+365, Routine
ALT/SGPT
Expected-S+28 Approximate, Expires-S+365, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC with DIFF, Total Bilirubin, AST, ALT
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Total Bilirubin greater
than 2.8 mg/dL or AST or ALT greater than 2.5 X ULN.
Nursing Procedure, Assessment and Monitoring
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/21/2016 2:09:48 PM Page 5 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, dasatinib will be ordered through the medication activity after the initial order.
Follow-Up
DAY 85 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC with DIFF, Total Bilirubin, AST, ALT
Cycle 5 – 5/8/2017 through 7/30/2017 (84 days), Planned
Day 1, Cycle 5 – Planned for 5/8/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); THERAPY: dasatinib 140 mg by mouth daily;
CYCLE LENGTH: 28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days;
COURSE: until disease progression.
Treatment Plan Summary (2)
DISEASE: Chronic Myeloid Leukemia (Chronic Phase); THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 28 days;
COURSE: 3 cycles followed by THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until disease
progression.
Treatment Plan Summary (3)
DISEASE: Chronic Myeloid Leukemia (Accelerated/Blast Phase); THERAPY: dasatinib 140 mg by mouth daily ; CYCLE LENGTH:
28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until
disease progression.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITH DIFFERENTIAL
Expected-S+84 Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S+84 Approximate, Expires-S+365, Routine
AST/SGOT
Expected-S+84 Approximate, Expires-S+365, Routine
ALT/SGPT
Expected-S+84 Approximate, Expires-S+365, Routine
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/21/2016 2:09:48 PM Page 6 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC with DIFF, Total Bilirubin, AST, ALT
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Total Bilirubin greater
than 2.8 mg/dL or AST or ALT greater than 2.5 X ULN.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, dasatinib will be ordered through the medication activity after the initial order.
Follow-Up
DAY 85 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC with DIFF, Total Bilirubin, AST, ALT
Cycle 6 – 7/31/2017 through 10/22/2017 (84 days), Planned
Day 1, Cycle 6 – Planned for 7/31/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); THERAPY: dasatinib 140 mg by mouth daily;
CYCLE LENGTH: 28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days;
COURSE: until disease progression.
Treatment Plan Summary (2)
DISEASE: Chronic Myeloid Leukemia (Chronic Phase); THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 28 days;
COURSE: 3 cycles followed by THERAPY: dasatinib 100 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until disease
progression.
Treatment Plan Summary (3)
DISEASE: Chronic Myeloid Leukemia (Accelerated/Blast Phase); THERAPY: dasatinib 140 mg by mouth daily ; CYCLE LENGTH:
28 days; COURSE: 3 cycles followed by THERAPY: dasatinib 140 mg by mouth daily; CYCLE LENGTH: 84 days; COURSE: until
disease progression.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITH DIFFERENTIAL
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/21/2016 2:09:48 PM Page 7 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

Expected-S+84 Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S+84 Approximate, Expires-S+365, Routine
AST/SGOT
Expected-S+84 Approximate, Expires-S+365, Routine
ALT/SGPT
Expected-S+84 Approximate, Expires-S+365, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC with DIFF, Total Bilirubin, AST, ALT
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Total Bilirubin greater
than 2.8 mg/dL or AST or ALT greater than 2.5 X ULN.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, dasatinib will be ordered through the medication activity after the initial order.
Follow-Up
DAY 85 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC with DIFF, Total Bilirubin, AST, ALT
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/21/2016 2:09:48 PM Page 8 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org